Abstracts tagged "Pediatric rheumatology"

Abstract Number: 0406 • ACR Convergence 2024
Delayed Diagnosis and Accrual of Joint Damage in Incident Cases of Juvenile Idiopathic Arthritis
Anna Costello¹, Cassandra Muir¹, Rui Xiao², Pamela Weiss³ and Irit Rasooly¹, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Timely diagnosis of Juvenile Idiopathic Arthritis (JIA) enables early initiation of therapy, prevents accrual of joint damage, and improves outcomes. Data regarding the diagnostic…
Abstract Number: 1068 • ACR Convergence 2024
Improving Health Numeracy Literacy in Pediatric Patients with SLE
Nicole Salach¹, Sarah Rogal¹, Jessica Simpson¹, Sangeeta Sule², Abigail Bosk³ and Catherine Park¹, ¹Children's National Hospital, Washington DC, DC, ²Children's National Hospital, Washington, DC, ³Children's National Hospital, Bethesda, DC
Background/Purpose: Health literacy is key to better patient outcomes. One aspect of health literacy that warrants additional investigation in patients who have systemic lupus erythematosus…
Abstract Number: 1271 • ACR Convergence 2024
Linkage of the Childhood Arthritis and Rheumatology Research Alliance Registry with the Pediatric Health Information System: Creation of a Comprehensive Childhood-Onset Lupus Dataset
Jordan Roberts¹, Anna Faino², Min-Lee Chang³, Jonathan Cogen⁴, Matt Hall⁵ and Esi Morgan¹, and for the CARRA Registry Investigators, ¹Seattle Children's Hospital, Seattle, WA, ²Seattle Children's Research Institute, Core for Biostatistics, Epidemiology and Analytics in Research, Seattle, ³Computational Health Informatics Program, Boston Children’s Hospital, Boston, MA, ⁴Seattle Children’s Hospital, Seattle, WA, ⁵Children’s Hospital Association, Lenexa, KS
Background/Purpose: Currently, no comprehensive national multipayer dataset with inpatient and outpatient data exists for childhood rheumatologic diseases, limiting the ability to study outcomes longitudinally and…
Abstract Number: 1452 • ACR Convergence 2024
Assessing Responsiveness of Outcome Measures for Children with Axial Juvenile Spondyloarthritis (JSpA)
Timothy Brandon¹, Rui Xiao², Cassandra Muir¹, Matthew Stoll³, Daniel Lovell⁴, Edward Oberle⁵, Nancy Chauvin⁶, Michael Francavilla⁷, Walter Maksymowych⁸ and Pamela Weiss⁹, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Nationwide Children's Hospital, Columbus, OH, ⁶The Imaging Institute @ The Cleveland Clinic, Cleveland, OH, ⁷Department of Radiology, Whiddon College of Medicine, University of South Alabama, Mobile, AL, ⁸University of Alberta, Edmonton, AB, Canada, ⁹Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Trials for patients with juvenile spondyloarthritis (JSpA) and axial disease are scarce. We assessed the responsiveness of measures for use in trials of patients…
Abstract Number: 1780 • ACR Convergence 2024
Next Generation Sequencing Analysis Reveals Complex Genetic Architecture of Childhood-onset Systemic Lupus Erythematosus
Laura Lewandowski¹, Linda Hiraki², Christiaan Scott³, Ana Barrera-Vargas⁴, Diana Gómez-Martin⁵, Michael Ombrello⁶, Ivona Aksentijevich⁷, Zuoming deng⁸, Anthony Musolf⁹, Subrata Paul¹⁰, Dan Hupalo¹¹, Clifton Dalgard¹¹, Sarfaraz Hasni¹², Earl Silverman¹³ and Mariana Kaplan¹⁴, ¹NIAMS, NIH, Bethesda, MD, ²The Hospital for Sick Children, Toronto, ON, Canada, ³Pediatric Rheumatology, Children’s Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada, ⁴Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Federal District, Mexico, ⁵INCMNSZ, Mexico, Distrito Federal, Mexico, ⁶National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), North Bethesda, MD, ⁷National Human Genome Research Institute, NIH, Bethesda, MD, ⁸National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, Bethesda, MD, ⁹Computational and Statistical Genomics Branch, NHGRI, NIH, Baltimore, MD, ¹⁰Collaborative Bioinformatics Resource, NIAID, NIH, Bethesda, MD, ¹¹The American Genome Center, Department of Anatomy, Physiology & Genetics, Uniformed Services University, Bethesda, MD, ¹²National Institutes of Health, Bethesda, MD, ¹³Silverman, Toronto, ON, Canada, ¹⁴NIAMS/NIH, Bethesda, MD
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a potentially life-threatening autoimmune disease. Childhood-onset SLE (cSLE) patients have younger disease onset and more severe disease than adults,…
Abstract Number: 2166 • ACR Convergence 2024
Nominal Group Technique to Identify What Adolescents with JIA and Parents of Children with JIA Consider When Making Treatment Change Decisions
Melissa Mannion¹, Livie Timmerman², Emily Smitherman¹, Jeffrey Curtis³ and Ronan O'Beirne¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Gardendale, AL, ³The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Juvenile idiopathic arthritis (JIA) is a life-long disease that often requires escalation of therapy to achieve disease control. The goal of this project was…
Abstract Number: 2196 • ACR Convergence 2024
Identifying Specific Criteria for Juvenile Systemic Sclerosis: A Comparison of Adult and Pediatric Ratings
Suzanne Li¹, Natalia Vasquez-Canizares², Clare Pain³, Marinka Twilt⁴, Amra Adrovic⁵, Abdulrahman Alrasheed⁶, Simone Appenzeller⁷, ADELE CIVINO⁸, narendra bagri⁹, Patricia Costa Reis¹⁰, Muserref Cucueoglu¹¹, Fatma Dedeoglu¹², samundeeswari Deepak¹³, Jianghong Deng¹⁴, Dalia El-Ghoneimy¹⁵, Ivan Foeldvari¹⁶, Fernando Garcia-Rodriguez¹⁷, Marija Jelusic¹⁸, Ankur Jindal¹⁹, Ozgur Kasapcopur²⁰, Maria Katsicas²¹, Archana Khan²², Raju Khubchandani²³, Meiping Lu²⁴, Hanna Lythgoe²⁵, edoardo marrani²⁶, Giorgia Martini²⁷, Takako Miyamae²⁸, Tomo Nozawa²⁹, Seza Ozen³⁰, Lidia Rutkowska-Sak³¹, Sunil Sampath¹³, Dieneke Schonenberg-Meinema³², Hongmei Song³³, Betul Sozeri³⁴, Hayakazu Sumida³⁵, Maria Teresa Terreri³⁶, Kathryn Torok³⁷, Seyma Turkmen³⁸, Dilara Unal³⁸, Gong Yinv³⁹, Emily Willis²⁵, Rongjun Zheng²⁴ and Brian Feldman⁴⁰, and Pediatric International Consortium for Scleroderma, ¹Hackensack Meridian School of Medicine, Joseph M. Sanzari Children's Hospital, Hackensack, NJ, ²Children's Hospital at Montefiore, Bronx, NY, ³Alderhey Children's NHS Foundation Trust, Liverpool, United Kingdom, ⁴Alberta Children's Hospital, Calgary, AB, Canada, ⁵Koc University Hospital, Istanbul, Turkey, ⁶King Abdullah Specialized Children Hospital, Riyadh, Saudi Arabia, ⁷Unicamp, Campinas, SP, Brazil, ⁸Pediatric Rheumatology "Vito Fazzi" Hospital LECCE, LECCE, Italy, ⁹All India Institute of Medical Sciences, New Delhi, Delhi, India, ¹⁰Hospital de Santa Maria, Lisbon, Portugal, ¹¹Hacettepe University, Ankara, Turkey, ¹²Boston Children's Hospital, Boston, MA, ¹³THE NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST, Newcastle upon Tyne, United Kingdom, ¹⁴Beijing Children's Hospital, Beijing, China, ¹⁵Children's Hospital, Ain Shams University, Cairo, Egypt, ¹⁶Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany, ¹⁷Universidad Autonoma de Nuevo Leon, Monterrey, NL, Mexico, ¹⁸University of Zagreb School of Medicine, University Hospital Centre Zagreb, Zagreb, Zagreb, Croatia, ¹⁹Postgraduate Institute of Medical Education and Research, Chandigarh, India, ²⁰Istanbul University-Cerrahpasa, Cerrahpasa Medical School, istanbul, Turkey, ²¹Hospital Garrahan, Buenos Aires, Argentina, ²²SRCC Children's Hospital, Mumbai, India, Mumbai, India, ²³The SRCC Children's Hospital, Mumbai, India, ²⁴Department of Rheumatology Immunology and Allergy, Children's Hospital of Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China (People's Republic), ²⁵Royal Manchester Children's Hospital, Manchester, United Kingdom, ²⁶Dipartimento Neurofarba, Università di Firenze, Firenze, Italy, ²⁷University of Udine University Hospital Santa Maria della Misericordia, Udine, Italy, ²⁸Tokyo Women's Medical University, Tokyo, Japan, ²⁹Yokohama City University, Yokohama, Japan, ³⁰Department of Pediatrics, Hacettepe University, Ankara, Turkey, ³¹National Institute of Geriatrics, Rheumatology and Rehabilitation, Warszawa, Poland, ³²Amsterdam University Medical Center, Amsterdam, Netherlands, ³³Peking Union Medical College Hospital, Beijing, China, ³⁴University of Health Sciences, Istanbul, Turkey, ³⁵The University of Tokyo, Tokyo, Japan, ³⁶UNIFESP, São Paulo, SP, Brazil, ³⁷Division of Rheumatology, Scleroderma Center, Department of Pediatrics, UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA, ³⁸University of Health Sciences, Umraniye Training and Research Hospital, Ankara, Turkey, ³⁹Children's Hospital Affiliated to Fudan University, Shanghai, China (People's Republic), ⁴⁰Division of Rheumatology, The Hospital for Sick Children; Departments of Pediatrics and Medicine, Faculty of Medicine; The Institute for Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada
Background/Purpose: Despite the high morbidity and mortality risk associated with juvenile systemic sclerosis (jSSc), evidence to guide management is limited. No jSSc clinical trials have…
Abstract Number: 2529 • ACR Convergence 2024
Improving Outcomes and Narrowing Disparities in Juvenile Idiopathic Arthritis (JIA): A Division-Wide, Equity-Focused Quality Improvement Project
Dori Abel¹, Kirsten Spichiger², Megan Roman², William Baar², Claire O'Malley², Jay Mehta¹, Terri Al'Hadi², Kerry Ferraro³, Denique Butler², Asia Wilson-Sanders², Catherine Lewis², Danielle Dodson⁴ and Jon Burnham¹, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²Children's Hospital of Philadelphia, Philadelphia, ³JIA parent and CHOP volunteer, Lower Gwynedd, PA, ⁴The Children's Hospital of Philadelphia, Philadelphia
Background/Purpose: Although new therapeutics and treat-to-target interventions have improved JIA care, pronounced racial and ethnic outcome disparities persist. At our center, the mean population-level clinical Juvenile…
Abstract Number: PP04 • ACR Convergence 2024
Involving Pediatric Patients in Their Own Care
Whitney LaBar, Lupus and Allied Diseases Association, Pleasanton, CA
Background/Purpose: When I was 14, I was diagnosed with thrombocytopenia, which led to more testing and a diagnosis of systemic lupus erythematosus (SLE). As a…
Abstract Number: 0385 • ACR Convergence 2024
Cross-cultural Validation of the “Effects of Youngsters-Eyesight on Quality of Life (EYE-Q)”: A Measure of Vision-related Quality of Life and Function in Childhood Uveitis
sheila Angeles-Han¹, Jordi Anton², Amra Adrovic³, Patricia Costa Reis⁴, Joke De Boer⁵, Séverine Guillaume-Czitrom⁶, Theresa Hennard⁷, Marija Jelusic⁸, Ozgur Kasapcopur⁹, Ilaria Maccora¹⁰, Hana Malcova¹¹, Joseph McDonald¹², Najima Mwase¹³, Gabriele Simonini¹⁴, Waheba Slamang¹⁵, Derrik du Toit¹⁶, Hendrike van Vollenhoven¹⁶ and Ivan Foeldvari¹⁷, ¹Cincinnati Children's Hospital, Cincinnati, OH, ²Hospital Sant Joan de Déu. Universitat de Barcelona, Esplugues de Llobregat (Barcelona), Spain, ³Deparment of Pediatric Rheumatology, Istanbul University-Cerrahpasa, Istanbul, Turkey, ⁴Hospital de Santa Maria, Lisbon, Portugal, ⁵Department of ophthalmology, University Medical Center Utrecht, Utrecht, Netherlands, ⁶University Hospital of Bicetre, Kremlin-Bicêtre, France, ⁷Cincinnati Children's Hospital and Medical Center, Cincinnati, OH, ⁸University of Zagreb School of Medicine, University Hospital Centre Zagreb, Zagreb, Zagreb, Croatia, ⁹Istanbul University-Cerrahpasa, Cerrahpasa Medical School, istanbul, Turkey, ¹⁰?PhD student, in the Area of Drugs and Innovative Treatments, NeuroFARBA Department, University of Florence. Meyer Children's Hospital, Florence Italy, Firenze, Florence, Italy, ¹¹FN Motol, Praha, Czech Republic, ¹²University of Chicago, Chicago, IL, ¹³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁴Meyer Children Hospital IRCCS; NEUROFARBA Department, University of Florence, Florence, Italy, ¹⁵University of Cape Town, Department of Child and Adolescent Health, Cape Town, South Africa, ¹⁶Red Cross Children’s Hospital, Cape Town, South Africa, ¹⁷Hamburg Centre for Pediatric and Adolescence Rheumatology, Hamburg, Germany
Background/Purpose: Childhood uveitis leads to sight-threatening complications in 50% of affected children and significantly impacts a child’s quality of life and function. The Multinational Interdisciplinary…
Abstract Number: 0409 • ACR Convergence 2024
Differences in Clinical Presentation and Outcomes Between Down Syndrome-Associated Arthritis and Juvenile Idiopathic Arthritis
Irene Chern¹, Jade Singleton², Xing Wang³ and Jordan Jones⁴, ¹St. Christopher's Hospital for Children, Philadelphia, PA, ²Seattle Children's Hospital, Seattle, ³Biostatistics Epidemiology and Analytics in Research, Seattle Children’s Research Institute, Seattle, WA, ⁴Children's Mercy Kansas City, Kansas City, MO
Background/Purpose: Down syndrome (DS), a disorder caused by triplication of chromosome 21, affects around 1 in 1000 births making it one of the most common…
Abstract Number: 1233 • ACR Convergence 2024
Narrative Medicine Intervention for Mental Wellbeing in Juvenile Myositis and Juvenile Idiopathic Arthritis
Aviya Lanis¹, Emily Steelquist², Christian Lood³ and Susan Shenoi⁴, ¹Seattle Children's Hospital, Seattle, WA, ²OHSU, Portland, OR, ³Division of Rheumatology, University of Washington, Seattle, WA, Seattle, WA, ⁴Seattle Children's Hospital and Research Center, Mercer Island, WA, WA
Background/Purpose: Children with juvenile dermatomyositis (JDM) and juvenile idiopathic arthritis (JIA) have impaired quality of life and increased rates of anxiety and depression (15-65%), even…
Abstract Number: 1272 • ACR Convergence 2024
Angiopoietin-2 and Soluble Tumor Necrosis Factor Receptor Type II Are Elevated in Treatment Naïve JDM Plasma and Associate with Increased Muscle Disease Activity and Decreased Nailfold Capillary Density
Sophia Matossian¹, Julie Sturza², Megan Mattichak¹, William Brodie¹, Christine Goudsmit¹, Nicholas McClellan¹, J. Michelle Kahlenberg¹, Pei-Suen Tsou¹ and Jessica Turnier³, ¹University of Michigan, Ann Arbor, MI, ²Michigan Medicine Biostatistics and Data Management, Ann Arbor, MI, ³University of Michigan, Saline, MI
Background/Purpose: Juvenile Dermatomyositis (JDM) is an autoimmune disease characterized by vasculopathy in skin and muscle, where endothelial cell (EC) dysfunction is thought to contribute to…
Abstract Number: 1591 • ACR Convergence 2024
Domains and Outcome Measures for the Assessment of Digital Vasculopathy and Raynaud Phenomenon in Juvenile Systemic Sclerosis: A Systematic Review
Valerio maniscalco¹, Simone Appenzeller², Jennifer lemon³, Lucy stead⁴, Natalia Vasquez Canizares⁵, Gabriele Simonini⁶, Suzanne Li⁷ and Clare Pain⁸, and IJOG study, ¹Santo Stefano Hospital; Meyer Children Hospital IRCCS, Firenze, Toscana, Italy, ²Unicamp, Campinas, SP, Brazil, ³Alder Hey Children's NHS Foundation Trust, Liverpool, ⁴Liverpool University, Liverpool, ⁵Children's Hospital at Montefiore; Albert Einstein College of Medicine;, New York, NY, ⁶Meyer Children Hospital IRCCS; NEUROFARBA Department, University of Florence, Florence, Italy, ⁷Hackensack University Medical Center, Hackensack, ⁸Alderhey Children's NHS Foundation Trust, Liverpool, United Kingdom
Background/Purpose: Juvenile systemic sclerosis (jSSc) is an orphan autoimmune disease that primary affect the vascular system determining multiple organ damage and reducing quality of life…
Abstract Number: 1781 • ACR Convergence 2024
Tear Proteomics as a Classifier of Disease Type and Activity Status in Pediatric Uveitis
Melissa Lerman¹, Devlin Eckardt¹, Stefanie Davidson² and Edward Behrens³, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²University of Pennsylvania/CHOP, Philadelphia, PA, ³Children's Hospital of Philadelphia, West Chester, PA
Background/Purpose: Measurement of proteins from tear fluid represents a non-invasive means to assess the local biology of ocular autoimmune disease such as uveitis. Pediatric uveitis…

« Previous Page
1
…
5
6
7
8
9
…
52
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.